{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:12Z","timestamp":1788865992373,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00198-026-07963-1","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:17:38Z","timestamp":1774909058000},"page":"1319-1328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The burden of bone disease in Duchenne muscular dystrophy: age-specific prevalence of osteoporosis and low bone density"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-8760","authenticated-orcid":false,"given":"Nat","family":"Nasomyont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hornung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan M.","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"1","key":"7963_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G (2020) Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 15(1):141. https:\/\/doi.org\/10.1186\/s13023-020-01430-8","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"7963_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01862-w","volume":"16","author":"SM Szabo","year":"2021","unstructured":"Szabo SM, Salhany RM, Deighton A, Harwood M, Mah J, Gooch KL (2021) The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis 16(1):237. https:\/\/doi.org\/10.1186\/s13023-021-01862-w","journal-title":"Orphanet J Rare Dis"},{"key":"7963_CR3","doi-asserted-by":"publisher","unstructured":"Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, STARnet MD. (2015) Corticosteroid treatments in males with Duchenne muscular dystrophy: treatment duration and time to loss of ambulation. J Child Neurol. 30(10):1275\u201380. https:\/\/doi.org\/10.1177\/0883073814558120.","DOI":"10.1177\/0883073814558120"},{"issue":"3","key":"7963_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251\u2013267. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"issue":"6","key":"7963_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","volume":"76","author":"S Joseph","year":"2019","unstructured":"Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V et al (2019) Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar database. JAMA Neurol 76(6):701\u2013709. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0242","journal-title":"JAMA Neurol"},{"issue":"11","key":"7963_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.nmd.2016.08.011","volume":"26","author":"C Tian","year":"2016","unstructured":"Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J et al (2016) Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Neuromuscul Disord 26(11):760\u2013767. https:\/\/doi.org\/10.1016\/j.nmd.2016.08.011","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"7963_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1515\/jpem.2000.13.6.571","volume":"13","author":"HM Frost","year":"2000","unstructured":"Frost HM, Schonau E (2000) The \u201cmuscle-bone unit\u201d in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 13(6):571\u2013590. https:\/\/doi.org\/10.1515\/jpem.2000.13.6.571","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"10","key":"7963_CR8","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1359\/jbmr.1999.14.10.1672","volume":"14","author":"DA Bailey","year":"1999","unstructured":"Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA (1999) A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res 14(10):1672\u20131679. https:\/\/doi.org\/10.1359\/jbmr.1999.14.10.1672","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7963_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","volume":"20","author":"CM Larson","year":"2000","unstructured":"Larson CM, Henderson RC (2000) Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 20(1):71\u201374","journal-title":"J Pediatr Orthop"},{"key":"7963_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2147\/TCRM.S143317","volume":"13","author":"D Feder","year":"2017","unstructured":"Feder D, Koch ME, Palmieri B, Fonseca FLA, Carvalho AAS (2017) Fat embolism after fractures in Duchenne muscular dystrophy: an underdiagnosed complication? A systematic review. Ther Clin Risk Manag 13:1357\u20131361. https:\/\/doi.org\/10.2147\/TCRM.S143317","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"7963_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00198-016-3774-5","volume":"28","author":"J Ma","year":"2017","unstructured":"Ma J, McMillan HJ, Karaguzel G, Goodin C, Wasson J, Matzinger MA et al (2017) The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int 28(2):597\u2013608. https:\/\/doi.org\/10.1007\/s00198-016-3774-5","journal-title":"Osteoporos Int"},{"issue":"2","key":"7963_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9(2):177\u2013189. https:\/\/doi.org\/10.1016\/S1474-4422(09)70272-8","journal-title":"Lancet Neurol"},{"issue":"4","key":"7963_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5","journal-title":"Lancet Neurol"},{"issue":"6","key":"7963_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/BPO.0000000000000817","volume":"38","author":"A Singh","year":"2018","unstructured":"Singh A, Schaeffer EK, Reilly CW (2018) Vertebral fractures in Duchenne muscular dystrophy patients managed with deflazacort. J Pediatr Orthop 38(6):320\u2013324. https:\/\/doi.org\/10.1097\/BPO.0000000000000817","journal-title":"J Pediatr Orthop"},{"issue":"5","key":"7963_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/jpem-2020-0680","volume":"34","author":"R Suthar","year":"2021","unstructured":"Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A et al (2021) Bone density and bone health alteration in boys with Duchenne muscular dystrophy: a prospective observational study. J Pediatr Endocrinol Metab 34(5):573\u2013581. https:\/\/doi.org\/10.1515\/jpem-2020-0680","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"7963_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00198-022-06578-6","volume":"34","author":"K Phung","year":"2023","unstructured":"Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M et al (2023) Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy. Osteoporos Int 34(1):147\u2013160. https:\/\/doi.org\/10.1007\/s00198-022-06578-6","journal-title":"Osteoporos Int"},{"issue":"6","key":"7963_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mus.27416","volume":"64","author":"N Nasomyont","year":"2021","unstructured":"Nasomyont N, Tian C, Hornung L, Khoury J, Hochwalt PM, Tilden JC et al (2021) The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis. Muscle Nerve 64(6):710\u2013716. https:\/\/doi.org\/10.1002\/mus.27416","journal-title":"Muscle Nerve"},{"issue":"4","key":"7963_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","volume":"22","author":"CR Shuhart","year":"2019","unstructured":"Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR et al (2019) Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 22(4):453\u2013471. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.001","journal-title":"J Clin Densitom"},{"key":"7963_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07651-6","author":"C De Ford","year":"2025","unstructured":"De Ford C, Guridi M, Chen Y, Murphy AP, Wood C, McMillan HJ et al (2025) Exploring the natural history of bone mineral density in Duchenne muscular dystrophy: a systematic literature review. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-025-07651-6","journal-title":"Osteoporos Int"},{"issue":"9","key":"7963_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"issue":"10","key":"7963_CR21","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1210\/jc.2011-1111","volume":"96","author":"BS Zemel","year":"2011","unstructured":"Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA et al (2011) Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab 96(10):3160\u20133169. https:\/\/doi.org\/10.1210\/jc.2011-1111","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7963_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1210\/clinem\/dgad435","volume":"109","author":"K Phung","year":"2024","unstructured":"Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M et al (2024) Risk factors associated with incident vertebral fractures in steroid-treated males with Duchenne muscular dystrophy. J Clin Endocrinol Metab 109(2):536\u2013548. https:\/\/doi.org\/10.1210\/clinem\/dgad435","journal-title":"J Clin Endocrinol Metab"},{"key":"7963_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bone.2018.07.019","volume":"116","author":"NJ Crabtree","year":"2018","unstructured":"Crabtree NJ, Adams JE, Padidela R, Shaw NJ, Hogler W, Roper H et al (2018) Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen. Bone 116:181\u2013186. https:\/\/doi.org\/10.1016\/j.bone.2018.07.019","journal-title":"Bone"},{"key":"7963_CR24","doi-asserted-by":"publisher","unstructured":"Gordon CM, Leonard MB, Zemel BS (2014) International Society for Clinical D. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom. 17(2):219\u201324. https:\/\/doi.org\/10.1016\/j.jocd.2014.01.007.","DOI":"10.1016\/j.jocd.2014.01.007"},{"key":"7963_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00576","volume":"11","author":"LM Ward","year":"2020","unstructured":"Ward LM (2020) Glucocorticoid-induced osteoporosis: why kids are different. Front Endocrinol (Lausanne) 11:576. https:\/\/doi.org\/10.3389\/fendo.2020.00576","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"7963_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nmd.2020.06.005","volume":"30","author":"C Tian","year":"2020","unstructured":"Tian C, Wong BL, Hornung L, Khoury JC, Rybalsky I, Shellenbarger KC et al (2020) Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. Neuromuscul Disord 30(7):599\u2013610. https:\/\/doi.org\/10.1016\/j.nmd.2020.06.005","journal-title":"Neuromuscul Disord"},{"key":"7963_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06951-z","author":"E Loscalzo","year":"2023","unstructured":"Loscalzo E, See J, Bharill S, Yousefzadeh N, Gough E, Wu M et al (2023) Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-023-06951-z","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07963-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07963-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07963-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:42Z","timestamp":1788865422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07963-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7963"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07963-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.N., L.H., J.K., and B.W. have no conflicts of interest to declare. C.T. has been a site PI for clinical trials and studies sponsored by Avexis, BioHaven, Bristol Myers Squibb, Capricor, Catabasis, FibroGen, Pfizer, PTC Therapeutics, Roche, Santhera, and Sarepta and has been a consultant for Biogen, Catalyst, Entrada, Regenxbio, Sarepta, and Solid Bioscience. M.R. has served as a consultant for Catalyst Pharmaceuticals, Inc.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}